Top Abstract Purchase Related
Home
>
Node
>
Subnode

Successful discontinuation of secondary prophylaxis for histoplasmosis after highly active antiretroviral therapy

Sun, H-Yun.; Chen, M-Yuan.; Hsieh, S-Min.; Hung, C-Ching.; Chang, S-Chwen.

Journal of the Formosan Medical Association 103(7): 546-548

2004

ISSN/ISBN: 0929-6646
PMID: 15318277
Document Number: 571120
Whether maintenance antifungal prophylaxis against histoplasmosis should be continued life-long in patients with immune restoration after highly active antiretroviral therapy (HAART) remains unclear. We report a case of disseminated histoplasmosis involving the skin, lung, gastrointestinal tract, mesentery, and retroperitoneum in a 33-year-old man from Thailand with acquired immunodeficiency syndrome. The patient was admitted to a hospital in Taiwan in May 1997. His symptoms improved after use of amphotericin B and itraconazole in addition to ileostomy to relieve the intestinal obstruction. After the start of HAART, he was able to discontinue itraconazole as maintenance therapy without relapse for 24 months.

Document emailed within 1 workday
Secure & encrypted payments

Vibhagool, A.; Sungkanuparph, S.; Mootsikapun, P.; Chetchotisakd, P.; Tansuphaswaswadikul, S.; Bowonwatanuwong, C.; Ingsathit, A. 2003: Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 36(10): 1329-1331
Mosam, A.; Shaik, F.; Uldrick, T.S.; Esterhuizen, T.; Friedland, G.H.; Scadden, D.T.; Aboobaker, J.; Coovadia, H.M. 2012: A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa Journal of Acquired Immune Deficiency Syndromes (1999) 60(2): 150-157
Mosam, A.; Shaik, F.; Uldrick, T.S.; Esterhuizen, T.; Friedland, G.H.; Scadden, D.T.; Aboobaker, J.; Coovadia, H.M. 2012: A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa Journal of Acquired Immune Deficiency Syndromes (1999) 60(2): 150-157
Sulaiman, M.M.; Shettima, J.; Ummate, I.; Arogundade, F.A.; Yusuph, H.; Nwankwo, E.; Sanusi, A.A.; Akinsola, A. 2022: Comparative Evaluation of Prevalence, Risk Factors, and Pathologic Features of Kidney Disease in Highly Active Antiretroviral Therapy-Naive and Highly Active Antiretroviral Therapy-Experienced Patients at a Tertiary Health Facility in Maiduguri, Northeastern Nigeria Saudi Journal of Kidney Diseases and Transplantation: An Official Publication of the Saudi Center for Organ Transplantation Saudi Arabia 33(1): 72-79
Tan, R.; Westfall, A.O.; Willig, J.H.; Mugavero, M.J.; Saag, M.S.; Kaslow, R.A.; Kempf, M.C. 2008: Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy Journal of Acquired Immune Deficiency Syndromes 47(5): 553-558
Chen, L.F.; Hoy, J.; Lewin, S.R. 2007: Ten years of highly active antiretroviral therapy for HIV infection Medical journal of Australia 186(3): 146-151
Barbaro, G.; Lucchini, A.; Barbarini, G. 2005: Highly active antiretroviral therapy in HIV-associated pulmonary hypertension Minerva Cardioangiologica 53(2): 153-154
Gates, A.E.; Kaplan, L.D. 2002: AIDS malignancies in the era of highly active antiretroviral therapy Oncology 16(5): 657-665; Discussion 665: 668-670
Edlin, B.R. 1999: Change of HAART. Highly active antiretroviral therapy Lancet 353(9167): 1888
Parakh, A.; Dubey, A.P.; Kumar, A.; Maheshwari, A. 2009: Lipodystrophy and metabolic complications of highly active antiretroviral therapy Indian Journal of Pediatrics 76(10): 1017-1021
Idiculla, J. 2011: Anthropometric changes in patients receiving highly active antiretroviral therapy (ART) Journal of the Association of Physicians of India 59: 530; Author Reply 530
Chu, J.H.; Gange, S.J.; Anastos, K.; Minkoff, H.; Cejtin, H.; Bacon, M.; Levine, A.; Greenblatt, R.M. 2005: Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy American Journal of Epidemiology 161(9): 881-890
Pearson, C.R.; Micek, M.; Simoni, J.M.; Matediana, E.; Martin, D.P.; Gloyd, S. 2006: Modified directly observed therapy to facilitate highly active antiretroviral therapy adherence in Beira, Mozambique. Development and implementation Journal of Acquired Immune Deficiency Syndromes 43(Suppl 1): S134-S141
Harvey, K.M.; Carrington, D.; Duncan, J.; Figueroa, J.P.; Hirschorn, L.; Manning, D.; Jackson, S. 2008: Evaluation of adherence to highly active antiretroviral therapy in adults in Jamaica West Indian Medical Journal 57(3): 293-297
Egger, M.; Junghans, C.; Friis Moller, N.; Lundgren, J.D. 2001: Highly active antiretroviral therapy and coronary heart disease: the need for perspective AIDS 15(Suppl 5): S193-S201
Deng, X.-j.; He, Y.; Yang, L.; Zou, S.-p.; Yang, H.; Zheng, Y.-h. 2011: The evaluation of four-year highly active antiretroviral therapy in HIV-1 infected patients Zhonghua Nei Ke Za Zhi 50(3): 230-234
Ezeanolue, E.E.; Stumpf, P.G.; Soliman, E.; Fernandez, G.; Jack, I. 2011: Contraception choices in a cohort of HIV+ women in the era of highly active antiretroviral therapy Contraception 84(1): 94-97
Nelwan, E.J. 2014: Adherence to highly active antiretroviral therapy (HAART) in HIV/AIDS patient Acta Medica Indonesiana 46(4): 273-274
Manfredi, R.; Calza, L. 2009: Malignancies not included among AIDS-defining disorders, in the era of highly active antiretroviral therapy Recenti Progressi in Medicina 100(12): 547-549
Sevastianova, K.; Sutinen, J.; Westerbacka, J.; Ristola, M.; Yki-Järvinen, H. 2005: Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy Antiviral Therapy 10(8): 925-935